William M Puszyk Selected Research

lexatumumab

5/2017	Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
1/2015	Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William M Puszyk Research Topics

Disease

4	Neoplasms (Cancer) 05/2017 - 02/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2017 - 01/2015
2	Down Syndrome (Down's Syndrome) 02/2009 - 01/2008
2	Aneuploidy (Aneuploid) 02/2009 - 01/2008
1	Carcinogenesis 01/2013
1	Hepatocellular Carcinoma (Hepatoma) 01/2013
1	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 01/2013
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2008

Drug/Important Bio-Agent (IBA)

2	lexatumumabIBA 05/2017 - 01/2015
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 05/2017 - 01/2015
2	sepantroniumIBA 05/2017 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 01/2015 - 01/2013
2	DNA (Deoxyribonucleic Acid)IBA 02/2009 - 01/2008
1	6- (4- (3- (methylsulfonyl)benzylamino)- 5- (trifluoromethyl)pyrimidin- 2- ylamino)- 3,4- dihydroquinolin- 2(1H)- oneIBA 05/2017
1	Death Domain ReceptorsIBA 05/2017
1	Small Interfering RNA (siRNA)IBA 05/2017
1	Focal Adhesion Protein-Tyrosine KinasesIBA 05/2017
1	SurvivinIBA 01/2015
1	bcl-2 Homologous Antagonist-Killer Protein (bcl 2 Homologous Antagonist Killer Protein)IBA 01/2015
1	Gemcitabine FDA Link 01/2015
1	Sorafenib (BAY 43-9006)FDA Link 01/2013
1	Biomarkers (Surrogate Marker)IBA 02/2009
1	Cell-Free Nucleic AcidsIBA 01/2008

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2015
1	Therapeutics 01/2013